We are live on ! Find out more
FO

FT Options Portfolio holdings

AUM $66.4M
1-Year Est. Return 18.48%
This Fund
S&P 500
This Quarter Est. Return
+2.11%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$66.4M
AUM Growth
+$8.29M
Cap. Flow
+$122M
Cap. Flow %
183.83%
Top 10 Hldgs %
32.21%
Holding
297
New
108
Increased
49
Reduced
51
Closed
72

Top Buys

Rank Stock Value
1
INCY icon
Incyte
INCY
+$3.53M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$2.94M
3
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$2.18M
4
ARAV
Aravive, Inc. Common Stock
ARAV
+$1.54M
5
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$1.37M

Top Sells

Rank Stock Value
1
GIS icon
General Mills
GIS
+$2.52M
2
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$2.31M
3
AMGN icon
Amgen
AMGN
+$2.08M
4
ABT icon
Abbott
ABT
+$1.72M
5
CLVS
Clovis Oncology, Inc.
CLVS
+$1.56M

Sector Composition

Rank Sector Weight
1 Healthcare 41.81%
2 Consumer Discretionary 7.1%
3 Consumer Staples 6.25%
4 Communication Services 0.99%
5 Materials 0.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KPTI icon
251
PUT
Karyopharm Therapeutics
KPTI
$216M
– –
-1,333
Closed -$28K
LULU icon
252
CALL
lululemon athletica
LULU
$13.2B
– –
-17,100
Closed -$59K
NBIX icon
253
CALL
Neurocrine Biosciences
NBIX
$17.2B
– –
-16,000
Closed -$24K
OZK icon
254
PUT
Bank OZK
OZK
$5.68B
– –
-15,000
Closed -$21K
PALI icon
255
Palisade Bio
PALI
$342M
– –
0
– -$15K
PALI icon
256
PUT
Palisade Bio
PALI
$342M
– –
0
– -$11K
PBYI icon
257
PUT
Puma Biotechnology
PBYI
$434M
– –
-61,800
Closed -$27K
PEP icon
258
PepsiCo
PEP
$187B
– –
-829
Closed -$95.8K
PEP icon
259
PUT
PepsiCo
PEP
$187B
– –
-45,000
Closed -$95K
PZZA icon
260
CALL
Papa John's
PZZA
$1.08B
– –
-15,000
Closed -$4K
QURE icon
261
CALL
uniQure
QURE
$2.77B
– –
-102,000
Closed -$19K
RCKT icon
262
PUT
Rocket Pharmaceuticals
RCKT
$376M
– –
-7,825
Closed -$39K
SCYX icon
263
CALL
SCYNEXIS
SCYX
$42.4M
– –
-125
Closed -$2K
STZ icon
264
CALL
Constellation Brands
STZ
$22.7B
– –
-14,000
Closed -$28K
STZ icon
265
PUT
Constellation Brands
STZ
$22.7B
– –
-10,000
Closed -$41K
TDG icon
266
CALL
TransDigm Group
TDG
$67.9B
– –
-5,000
Closed -$2K
TXT icon
267
CALL
Textron
TXT
$15.9B
– –
-700
Closed -$1K
TXT icon
268
Textron
TXT
$15.9B
– –
-3,371
Closed -$159K
TXT icon
269
PUT
Textron
TXT
$15.9B
– –
-6,300
Closed -$11K
XBI icon
270
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.4B
– –
-15,000
Closed -$17K
XBI icon
271
State Street SPDR S&P Biotech ETF
XBI
$10.4B
– –
-4,150
Closed -$320K
XBI icon
272
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
– –
-45,000
Closed -$94K
CMRX
273
DELISTED
Chimerix, Inc.
CMRX
– –
-75,239
Closed -$370K
ZYNE
274
CALL
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
– –
-7,000
Closed -$5K
AERI
275
PUT
DELISTED
Aerie Pharmaceuticals
AERI
– –
-15,000
Closed -$43K
8 9 10
11
12

Similar funds

MC
Micawber Capital Seattle, Washington $62.9M AUM 20.32% 1-Year Est. Return
FIM
Friedberg Investment Management Houston, Texas $61.9M AUM 20.07% 1-Year Est. Return
TLIC
Thai Life Insurance Company Bangkok, Thailand $71M AUM 20.14% 1-Year Est. Return
MKCM
Mount Kellett Capital Management New York $61M AUM 12.22% 1-Year Est. Return
ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
MFM
Marianas Fund Management New York $58.1M AUM 10.84% 1-Year Est. Return
VE
Vega Energy New York $75.5M AUM 15.36% 1-Year Est. Return
GFWEV
G.F.W. Energy VIII Irving, Texas $76.3M AUM 11.41% 1-Year Est. Return

FT Options's Q3 2017 Portfolio in Review

As of Q3 2017, FT Options held 297 positions worth $66.4M, up 14% from $58.1M the previous quarter. Its ten largest holdings account for 32% of the portfolio.

FT Options deployed $122M of net new capital in Q3 2017, opening 108 new positions and adding to 49 existing holdings. Its largest new stake was Incyte: 27,887 shares worth $3.26M.

By sector, the portfolio is most concentrated in Healthcare at 42% of assets, up from 38% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.

On the sell side, the largest reduction was General Mills, an estimated $2.52M trimmed.

  • FT Options's largest Q3 2017 buy was Incyte: 27,887 shares worth $3.26M.
  • FT Options added most to Sio Gene Therapies Inc. Common Stock in Q3 2017, an estimated $1.37M increase.
  • FT Options's biggest Q3 2017 reduction was General Mills, cutting an estimated $2.52M.
  • FT Options fully exited Portola Pharmaceuticals, Inc. in Q3 2017, selling an estimated $2.31M.
  • FT Options's ten largest holdings make up 32% of its $66.4M portfolio in Q3 2017.
  • FT Options opened 108 new positions and closed 72 in Q3 2017.
  • FT Options's portfolio value rose 14% quarter-over-quarter to $66.4M.

Based on FT Options's 13F filing for Q3 2017, filed 13 Nov 2017.